Drug Trial Radar · NCT01037205
Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza
Last checked: Nov 19, 2026Latest source record: Apr 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
264
Actual
Start
Dec 2009
Primary completion
Sep 2011
Study completion Sep 2011
Sponsor
- Lead sponsor
- Ansun Biopharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH)
- First posted
- Dec 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol will seek to enroll adult otherwise healthy subjects presenting with influenza-like illness (ILI). Subjects will enter the study based on listed inclusion/exclusion criteria, including a positive diagnostic test for influenza virus (IFV).
Conditions
- Influenza
Interventions
DAS181 dry powder, formulation F02Drug
10 mg delivered dose DAS181 in clear HPMC #3 Capsules
Respitose ML006 (DMV-Fonterra)Drug
Lactose monohydrate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Level of influenza viral load as Area Under the Curve at Day 5 (AUC0 d5) as measured by a) quantitative polymerase chain reaction (quantitative PCR) and b) 50% tissue culture infectious dose (TCID50) in cell cultureTime frame: 28 days
- Safety and toxicity profile: Unacceptable Serious Adverse EventsTime frame: 28 days
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Carmichael, California
Site not named
Chula Vista, California
Site not named
La Mesa, California
Site not named
Lincoln, California
Site not named
Los Angeles, California
Site not named
Orange, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Hialeah, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Boise, Idaho
Site not named
Covington, Louisiana
Site not named
Silver Spring, Maryland
Site not named
North Dartmouth, Massachusetts
Site not named
Bellevue, Nebraska
Site not named
Henderson, Nevada
Site not named
Las Vegas, Nevada
Site not named
Stony Brook, New York
Site not named
Canton, Ohio
Site not named
Dayton, Ohio
Site not named
Franklin, Ohio
Site not named
Groveport, Ohio
Site not named
Miamisburg, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Tulsa, Oklahoma
Site not named
Ashland, Oregon
Site not named
Lansdale, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Myrtle Beach, South Carolina
Site not named
Simpsonville, South Carolina
Site not named
Rapid City, South Dakota
Site not named
Johnson City, Tennessee
Site not named
Austin, Texas
Site not named
Georgetown, Texas
Site not named
San Antonio, Texas
Site not named
Salt Lake City, Utah
Site not named
West Point, Utah
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.